Selected Publications

Myc drives Pten/ p53-deficient proliferation and metastasis due to Il6-secretion and Akt-suppression via Phlpp2.
Dawid G. Nowak, Hyejin Cho, Tali Herzka, Kaitlin Watrud, Daniel V. DeMarco, Victoria M.Y. Wang, Serif Senturk, Christof Fellmann, David Ding, Tumas Beinortas, David Kleinman, Muhan Chen, Raffaella Sordella, John E. Wilkinson, Mireia Castillo-Martin, Carlos Cordon-Cardo, Brian D. Robinson & Lloyd C. Trotman.
Cancer Discov. 2015 Mar 31. pii: CD-14-1113. PMID: 25829425

PTEN Functions by Recruitment to Cytoplasmic Vesicles.
Naguib A, Bencze G, Cho H, Zheng W, Tocilj A, Elkayam E, Faehnle CR, Jaber N, Pratt CP, Chen M, Zong WX, Marks MS, Joshua-Tor L, Pappin DJ, Trotman LC.
Molecular Cell. 2015 Apr. PMID: 25866245

Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome.
Cho H, Herzka T, Stahlhut C, Watrud K, Robinson BD, Trotman LC.
Methods. 2015 Jan 12. PMID: 25592467

p53 mutations change phosphatidylinositol acyl chain composition.
Naguib A, Bencze G, Engle DD, Chio II, Herzka T, Watrud K, Bencze S, Tuveson DA, Pappin DJ, Trotman LC.
Cell Reports, 2015 Jan 6. PMID: 25543136

RapidCaP, a novel GEM model for analysis and therapy of metastatic prostate cancer reveals Myc as a driver of Pten-mutant metastasis.
Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LC.
Cancer Discov. 2014 Jan 20. PMID: 24444712

Prostate Cancer Genetic-susceptibility Locus on Chromosome 20q13 is Amplified and Coupled to Androgen Receptor-regulation in Metastatic Tumors.Labbe, D. P., Nowak, D. G., Deblois, G., Lessard, L., Giguere, V., Trotman, L. C. Tremblay, M. L.
Molecular Cancer Res. 2013 Dec 30. PMID: 24379448.

Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia.
Howitt J, Lackovic J, Low LH, Naguib A, Macintyre A, Goh CP, Callaway JK, Hammond V, Thomas T, Dixon M, Putz U, Silke J, Bartlett P, Yang B, Kumar S, Trotman LC, Tan SS.
J Cell Biol. 2012 Jan 2.

Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.
Chen, M., Pratt, C. P., Zeeman, M. E., Schultz, N., Taylor, B.S., O’Neill, A., Castillo-Martin, M., Nowak, D. G., Naguib, A., Navin, N., Atwal, G.S., Sander C., Gerald W.L., Cordon-Cardo C., Newton A.C., Carver B.S., Trotman L.C.
Cancer Cell. 2011 Aug 16;20(2):173-86.



Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy.
Chen M, Nowak DG, Trotman LC.
Clinical Cancer Res. 2014 Jun 15. PMID: 24928944

Turning Off AKT: PHLPP as a Drug Target.
Newton AC. and Trotman LC.
Annual Review of Pharmacol Toxicol. 2014 Jan 6;54:537-58. PMID: 24392697.

PTEN Plasticity - How the Taming of a Lethal Gene Can Go too Far.
Naguib, A., Trotman, L.C.
Trends in Cell Biology. 2013 Apr 8. PMID: 23578748

Calling on the cancer sleuths: how cell biologists will do the detective legwork of the postcancer genome era.
Trotman LC.
Molecular Biology of the Cell. 2011 Mar;22(6):715.PMID: 21406578 

Towards patient-based cancer therapeutics.
The Cancer Target Discovery and Development Network, Schreiber SL, Shamji AF, Clemons PA, Hon C, Koehler AN, Munoz B, Palmer M, Stern AM, Wagner BK, Powers S, Lowe SW, Guo X, Krasnitz A, Sawey ET, Sordella R, Stein L, Trotman LC, Califano A, Dalla-Favera R, Ferrando A, Iavarone A, Pasqualucci L, Silva J, Stockwell BR, Hahn WC, Chin L, Depinho RA, Boehm JS, Gopal S, Huang A, Root DE, Weir BA, Gerhard DS, Zenklusen JC, Roth MG, White MA, Minna JD, Macmillan JB, Posner BA.
Nat Biotechnol. 2010 Sep;28(9):904-906. PMID: 20829823

New views into the prostate cancer genome.
Trotman L, Powers S.
Cancer Cell. 2010 Jul 13;18(1):1-2. PMID: 20609345

Trotman LC. In Ralph A. Bradshaw and Edward A. Dennis, editors: Handbook of Cell Signaling 2nd edition, Oxford:Academic Press, 2009, pp. 849-854.

Lloyd Trotman: of mice and men, cancer, and PTEN.
Interviewed by Caitlin Sedwick.
J Cell Biol. 2008 May 5;181(3):402-3.


see also news